Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,463 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03326674 | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC(CONTESSA) | terminated | Phase 3 | 685 | Odonate Therapeutics, Inc.INDUSTRY | 19 | Jul 30, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY |
| 41 |
| Jul 29, 2021 |
| clinicaltrials |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.(RESPONSE-2) | completed | Phase 3 | 149 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 20, 2021 | clinicaltrials |
| NCT03196791 | Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient | completed | Phase 3 | 196 | Korea University Anam HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting(NALA) | completed | Phase 3 | 621 | Puma Biotechnology, Inc.INDUSTRY | 28 | Jun 11, 2021 | clinicaltrials |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102)(BEACON) | completed | Phase 3 | 852 | Nektar TherapeuticsINDUSTRY | 11 | Jun 1, 2021 | clinicaltrials |
| NCT02130557 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 3 | 536 | PfizerINDUSTRY | 26 | May 18, 2021 | clinicaltrials |
| NCT01798056 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy | completed | Phase 3 | 237 | GlaxoSmithKlineINDUSTRY | 6 | May 13, 2021 | clinicaltrials |
| NCT03170050 | Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds | completed | Phase 3 | 107 | Yooyoung Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib(CELESTIAL) | completed | Phase 3 | 707 | ExelixisINDUSTRY | 19 | May 6, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT02057666 | Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer(TasQ003) | terminated | Phase 3 | 146 | IpsenINDUSTRY | 3 | Apr 23, 2021 | clinicaltrials |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer(EXAM) | completed | Phase 3 | 330 | ExelixisINDUSTRY | 24 | Apr 20, 2021 | clinicaltrials |
| NCT02260804 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | completed | Phase 3 | 258 | CelltrionINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01763164 | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | completed | Phase 3 | 402 | PfizerINDUSTRY | 27 | Mar 22, 2021 | clinicaltrials |
| NCT04803266 | Elective Internal Mammary Node Irradiation in Women With Node-positive Breast Cancer | unknown | Phase 3 | 747 | Yonsei UniversityOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT00073528 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 1,286 | Novartis PharmaceuticalsINDUSTRY | 29 | Feb 24, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT02039726 | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | completed | Phase 3 | 367 | Daiichi SankyoINDUSTRY | 19 | Feb 24, 2021 | clinicaltrials |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 17 | Feb 16, 2021 | clinicaltrials |
| NCT02369874 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer(EAGLE) | completed | Phase 3 | 736 | AstraZenecaINDUSTRY | 24 | Feb 10, 2021 | clinicaltrials |
| NCT03162796 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)(Discover-1) | completed | Phase 3 | 383 | Janssen Research & Development, LLCINDUSTRY | 13 | Feb 3, 2021 | clinicaltrials |
| NCT01271712 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)(GRID) | completed | Phase 3 | 199 | BayerINDUSTRY | 17 | Jan 29, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer(ATRACT-1) | terminated | Phase 3 | 1,285 | Novartis PharmaceuticalsINDUSTRY | 26 | Dec 24, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)(Javelin DLBCL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT02625623 | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | completed | Phase 3 | 371 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Nov 24, 2020 | clinicaltrials |
| NCT01235962 | A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)(PROTECT) | completed | Phase 3 | 1,538 | Novartis PharmaceuticalsINDUSTRY | 26 | Nov 23, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
| NCT01955837 | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia(TERRA) | completed | Phase 3 | 406 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 3 | Nov 17, 2020 | clinicaltrials |
| NCT01102426 | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma(ADMYRE) | completed | Phase 3 | 255 | PharmaMarINDUSTRY | 19 | Nov 10, 2020 | clinicaltrials |
| NCT00080301 | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 752 | R-PharmINDUSTRY | 22 | Nov 2, 2020 | clinicaltrials |
| NCT00082433 | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 1,221 | R-PharmINDUSTRY | 29 | Nov 2, 2020 | clinicaltrials |
| NCT02114359 | Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer | completed | Phase 3 | 111 | Seoul National University HospitalOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT00004917 | Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | completed | Phase 3 | — | Radiation Therapy Oncology GroupNETWORK | 3 | Oct 22, 2020 | clinicaltrials |
| NCT02923921 | Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer(Sequoia) | completed | Phase 3 | 567 | Eli Lilly and CompanyINDUSTRY | 13 | Oct 19, 2020 | clinicaltrials |
| NCT02809053 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma(RAMO-2) | completed | Phase 3 | 315 | Archigen Biotech LimitedINDUSTRY | 14 | Oct 8, 2020 | clinicaltrials |
| NCT01544179 | A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone(IMPRESS) | completed | Phase 3 | 265 | AstraZenecaINDUSTRY | 11 | Sep 25, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT01610284 | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor(BELLE-2) | completed | Phase 3 | 1,147 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 25, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials